Drug Profile
Research programme: tropical disease therapeutics - Astellas/DNDi/Unknown Pharmaceutical
Latest Information Update: 28 Apr 2022
Price :
$50
*
At a glance
- Originator Astellas Pharma; Drugs for Neglected Diseases Initiative Foundation; Unknown
- Class Antiparasitics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Chagas disease; Leishmaniasis
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for research development in Chagas-disease in Japan
- 28 Apr 2022 No recent reports of development identified for research development in Chagas-disease in Switzerland
- 28 Apr 2022 No recent reports of development identified for research development in Leishmaniasis in Japan